The DOI matches its Crossref record; 293 of the 293 references it cites were found in a registry or an index.
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–293 of 293
ImmTACs for targeted cancer therapy: Why, what, how, and which
Oates, J., Hassan, N. J., & Jakobsen, B. K. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.024 · Cited by 90
A quantitative comparison of cytosolic delivery via different protein uptake systems
Verdurmen, W. P. R., Mazlami, M., & Plückthun, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-13469-y · Cited by 90
Delivery of Antibody Mimics into Mammalian Cells via Anthrax Toxin Protective Antigen
Liao, X., Rabideau, A. E., & Pentelute, B. L. (2014) · ChemBioChem · doi:10.1002/cbic.201402290 · Cited by 88
Chodorge, M., Züger, S., Stirnimann, C. U., Briand, C., Jermutus, L., Grütter, M. G., & Minter, R. (2012) · Cell Death and Differentiation · doi:10.1038/cdd.2011.208 · Cited by 87
Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection
Zhukovsky, E. A., Morse, R. J., & Maus, M. V. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.02.006 · Cited by 86
Insights into the molecular basis of a bispecific antibody's target selectivity
Mazor, Y., Hansen, A. M., Yang, C., Chowdhury, P. S., Wang, J., Stephens, G. L., Wu, H., & Dall’Acqua, W. F. (2015) · mAbs · doi:10.1080/19420862.2015.1022695 · Cited by 85
Koussoroplis, S. J., Paulissen, G., Tyteca, D., Goldansaz, H., Todoroff, J., Barilly, C., Uyttenhove, C., Snick, J. V., Cataldo, D. D., & Rita Vanbever, A. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.021 · Cited by 85
Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies
Proetzel, G., & Roopenian, D. C. (2013) · Methods · doi:10.1016/j.ymeth.2013.07.005 · Cited by 84
Beyersdorf, N., Hanke, T., Kerkau, T., & Hünig, T. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.042564 · Cited by 84
A review of blinatumomab, a novel immunotherapy
Newman, M. J., & Benani, D. J. (2015) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155215618770 · Cited by 84
Pharmacological modulation of GITRL/GITR system: therapeutic perspectives
Nocentini, G., Ronchetti, S., Petrillo, M. G., & Riccardi, C. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01753.x · Cited by 83
Bumbaca Yadav, D., Sharma, V. K., Boswell, C. A., Hotzel, I., Tesar, D., Shang, Y., Ying, Y., Fischer, S. K., Grogan, J. L., Chiang, E. Y., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.692434 · Cited by 82
Schneider, H., Chaovapong, W., Matthews, D. J., Karkaria, C. E., Cass, R. T., Zhan, H., Boyle, M., Lorenzini, T., Elliott, S., & Giebel, L. B. (1997) · Blood · doi:10.1182/blood.v89.2.473 · Cited by 82
Verdurmen, W. P. R., Luginbühl, M., Honegger, A., & Plückthun, A. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.019 · Cited by 81
Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins
Smith, A. M., Manoli, H., Jaw, S., Frutoz, K., Epstein, A. L., Khawli, L. A., & Theil, F. (2016) · Journal of Immunology Research · doi:10.1155/2016/2342187 · Cited by 81
Activation of the Erythropoietin (EPO) Receptor by Bivalent Anti-EPO Receptor Antibodies
Elliott, S., Lorenzini, T., Yanagihara, D. L., Chang, D., & Elliott, G. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.40.24691 · Cited by 80
Dienstmann, R., Patnaik, A., Garcia-Carbonero, R., Cervantes, A., Benavent, M., Roselló, S., Tops, B. B. J., van der Post, R. S., Argilés, G., Skartved, N. J. Ø., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1432 · Cited by 77
Liu, Z., Gunasekaran, K., Wang, W., Razinkov, V. I., Sekirov, L., Leng, E. C., Sweet, H., Foltz, I. N., Howard, M., Rousseau, A.-M., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.513366 · Cited by 76
Harris, M. S., Hartman, D. S., Lemos, B. R., Erlich, E. C., Spence, S. C., Kennedy, S., Ptak, T., Pruitt, R. E., Vermeire, S. A. R. A., & Fox, B. S. (2016) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjw036 · Cited by 76
A novel screening method to assess developability of antibody-like molecules
Kohli, N., Jain, N., Geddie, M. L., Razlog, M., Xu, L., & Lugovskoy, A. A. (2015) · mAbs · doi:10.1080/19420862.2015.1048410 · Cited by 74
Choi, D.-K., Bae, J., Shin, S.-M., Shin, J.-Y., Kim, Y., & Kim, Y. (2014) · mAbs · doi:10.4161/mabs.36389 · Cited by 73
Mimoto, F., Igawa, T., Kuramochi, T., Katada, H., Kadono, S., Kamikawa, T., Shida-Kawazoe, M., & Hattori, K. (2013) · mAbs · doi:10.4161/mabs.23452 · Cited by 73
Antibody therapies and their challenges in the treatment of age-related macular degeneration
Volz, C., & Pauly, D. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.02.020 · Cited by 73
Martínez‐Forero, I., Azpilikueta, A., Bolaños, E., Nistal‐Villán, E., Palazón, A., Teijeira, Á., Pérez-Chacón, G., Morales‐Kastresana, A., Murillo, O., Jure‐Kunkel, M., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203010 · Cited by 73
Improved Lysosomal Trafficking Can Modulate the Potency of Antibody Drug Conjugates
DeVay, R. M., Delaria, K., Zhu, G., Holz, C., Foletti, D. L., Sutton, J. E., Bolton, G. L., Dushin, R. G., Bee, C., Pons, J., et al. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00013 · Cited by 73
The Airways, a Novel Route for Delivering Monoclonal Antibodies to Treat Lung Tumors
Maillet, A., Guilleminault, L., Lemarié, É., Lerondel, S., Azzopardi, N., Montharu, J., Congy‐Jolivet, N., Reverdiau, P., Legrain, B., Parent, C., et al. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0442-5 · Cited by 72
Shatz-Binder, W., Hass, P. E., Mathieu, M. A., Kim, H. S., Leach, K., Zhou, M., Crawford, Y., Shen, A. Y., Wang, K., Chang, D. P., et al. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00345 · Cited by 72
Monoclonal antibodies to purified muscarinic receptor display agonist-like activity.
Leiber, D., Harbon, S., Guillet, J. G., et al. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.14.4331 · Cited by 71
Antibody-Mediated Activation of FGFR1 Induces FGF23 Production and Hypophosphatemia
Wu, A.-L., Feng, B., Chen, M. Z., Kolumam, G. A., Zavala‐Solorio, J., Wyatt, S. K., Gandham, V. D., Carano, R. A. D., & Sonoda, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057322 · Cited by 71
pH-dependent antigen-binding antibodies as a novel therapeutic modality
Igawa, T., Mimoto, F., & Hattori, K. (2014) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2014.08.003 · Cited by 70
Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody
Zhang, D., Goldberg, M. V., & Chiu, M. L. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.757773 · Cited by 68
Bootz, F., & Neri, D. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.10.012 · Cited by 67
Design and Pharmacokinetic Characterization of Novel Antibody Formats for Ocular Therapeutics
Gadkar, K. G., Pastuskovas, C. V., LeCouter, J. E., Elliott, J. M., Zhang, J., Lee, C. V., Sanowar, S., Fuh, G., Kim, H. S., Lombana, T. N., et al. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-17108 · Cited by 67
White, A. L., Dou, L., Chan, H. T. C., Field, V. L., Mockridge, C. I., Moss, K., Williams, E. L., Booth, S. G., French, R. R., Potter, E. A., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1303204 · Cited by 66
Woyach, J. A., Awan, F. T., Flinn, I. W., et al. (2014) · Blood · doi:10.1182/blood-2014-08-593269 · Cited by 66
A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor
Orita, T., Tsunoda, H., Yabuta, N., Nakano, K., Yoshino, T., Hirata, Y., Ohtomo, T., Nezu, J., Sakumoto, H., Ono, K., et al. (2004) · Blood · doi:10.1182/blood-2004-04-1482 · Cited by 65
Engineering of stable bispecific antibodies targeting IL-17A and IL-23
Mabry, R., Lewis, K. E., Moore, M. D., McKernan, P. A., Bukowski, T. R., Bontadelli, K., Brender, T., Okada, S. L., Lum, K. D., West, J. W., et al. (2009) · Protein Engineering Design and Selection · doi:10.1093/protein/gzp073 · Cited by 64
Datta‐Mannan, A., Chow, C.-K., Dickinson, C. D., Driver, D. A., Lu, J., Witcher, D. R., & Wroblewski, V. J. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.045864 · Cited by 64
Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab
Ramakrishna, V., Sundarapandiyan, K., Zhao, B., Bylesjö, M., Marsh, H. C., & Keler, T. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0080-2 · Cited by 64
Cook, E. M., Lindorfer, M. A., van der Horst, H. J., Oostindie, S. C., Beurskens, F. J. M., Schuurman, J., Zent, C. S., Burack, R., Parren, P. W. H. I., & Taylor, R. P. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600648 · Cited by 64
Modulation of antibody effector function
Desjarlais, J. R., & Lazar, G. A. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.03.018 · Cited by 63
Self-citationBhol, K. C., Tracey, D. E., Lemos, B. R., Lyng, G. D., Erlich, E. C., Keane, D. M., Quesenberry, M. S., Holdorf, A. D., Schlehuber, L. D., Clark, S., et al. (2013) · Inflammatory Bowel Diseases · doi:10.1097/mib.0b013e3182a11958 · Cited by 63
Nayak, S., Griffiss, J. M., McKenzie, R., Fuchs, E. J., Jurao, R. A., An, A. T., Ahene, A. B., Tomic, M. T., Hendrix, C. W., & Zenilman, J. M. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02830-14 · Cited by 62
Opportunities and challenges for TCR mimic antibodies in cancer therapy
Chang, A. Y., Gejman, R. S., Brea, E. J., Oh, C. Y., Mathias, M. D., Pankov, D., Casey, E. R., Dao, T., & Scheinberg, D. A. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1176138 · Cited by 62
Chu, S. Y., Yeter, K. C., Kotha, R., Pong, E., Miranda, Y., Phung, S., Chen, H., Lee, S., Leung, I., Bonzon, C., et al. (2013) · Arthritis & Rheumatology · doi:10.1002/art.38334 · Cited by 61
Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic
Kearns, J. D., Bukhalid, R. A., Sevecka, M., Tan, G., Gerami-Moayed, N., Werner, S. L., Kohli, N., Burenkova, O. V., Sloss, C. M., King, A. M., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0772 · Cited by 60
Lavoisier, A., & Schlaeppi, J.-M. (2014) · mAbs · doi:10.4161/19420862.2014.985544 · Cited by 59
Agrahari, V., Agrahari, V., Mandal, A., Pal, D., & Mitra, A. K. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2017.1272569 · Cited by 59
Long-acting protein drugs for the treatment of ocular diseases
Ghosh, J. G., Nguyen, A. A., Bigelow, C. E., Poor, S. H., Qiu, Y., Rangaswamy, N. V., Ornberg, R., Jackson, B., Mak, H., Ezell, T., et al. (2017) · Nature Communications · doi:10.1038/ncomms14837 · Cited by 59
Niwa, R., & Satoh, M. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24316 · Cited by 58
Nebulized Anti–IL-13 Monoclonal Antibody Fab′ Fragment Reduces Allergen-Induced Asthma
Hacha, J., Tomlinson, K. L., Maertens, L., Paulissen, G., Rocks, N., Foidart, J., Noël, A., Palframan, R. T., Gueders, M. M., & Cataldo, D. D. (2012) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2012-0031oc · Cited by 58
Pardridge, W. M. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1230195 · Cited by 55
Wu, J., Schultz, J. S., Weldon, C. L., Sule, S. V., Chai, Q., Geng, S. B., Dickinson, C. D., & Tessier, P. M. (2015) · Protein Engineering Design and Selection · doi:10.1093/protein/gzv045 · Cited by 52
Vugmeyster, Y., Szklut, P., Wensel, D. L., Ross, J. E., Xu, X., Awwad, M., Gill, D. S., Tchistiakov, L., & Warner, G. L. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0405-x · Cited by 51
Datta‐Mannan, A., Croy, J. E., Schirtzinger, L., Torgerson, S., Breyer, M. D., & Wroblewski, V. J. (2016) · mAbs · doi:10.1080/19420862.2016.1178435 · Cited by 51
Target-independent variable region mediated effects on antibody clearance can be FcRn independent
Kelly, R. L., Yu, Y., Sun, T., Caffry, I., Lynaugh, H., Brown, M. E., Jain, T. S., Xu, Y., & Wittrup, K. D. (2016) · mAbs · doi:10.1080/19420862.2016.1208330 · Cited by 49
Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody
Zheng, S., Moores, S. L., Jarantow, S. W., Pardinas, J. R., Chiu, M. L., Zhou, H., & Wang, W. (2016) · mAbs · doi:10.1080/19420862.2015.1136762 · Cited by 48
Inhaled protein/peptide-based therapies for respiratory disease
Fellner, R. C., Terryah, S. T., & Tarran, R. (2016) · Molecular and Cellular Pediatrics · doi:10.1186/s40348-016-0044-8 · Cited by 48
Approaches to Mitigate the Unwanted Immunogenicity of Therapeutic Proteins during Drug Development
Salazar‐Fontana, L. I., Desai, D. D., Khan, T. A., Pillutla, R. C., Prior, S., Ramakrishnan, R., Schneider, J., & Joseph, A. M. (2017) · The AAPS Journal · doi:10.1208/s12248-016-0030-z · Cited by 47
Zhou, Q.-H., Boado, R. J., Lu, J. Z., Hui, E. K., & Pardridge, W. M. (2010) · Molecular Pharmaceutics · doi:10.1021/mp1001763 · Cited by 46
A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life
Souders, C. A., Nelson, S., Wang, Y., Crowley, A. R., Klempner, M. S., & Thomas, W. D. (2015) · mAbs · doi:10.1080/19420862.2015.1054585 · Cited by 45
Wu, Y., West, A. P., Kim, H. J., Thornton, M. E., Ward, A. C., & Björkman, P. J. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.11.015 · Cited by 45
Szili, D., Cserhalmi, M., Bankó, Z., Nagy, G., Szymkowski, D. E., & Sármay, G. (2014) · mAbs · doi:10.4161/mabs.28841 · Cited by 45
Zhou, Q.-H., Boado, R. J., Lu, J. Z., Hui, E. K., & Pardridge, W. M. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.031534 · Cited by 45
Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates
Dostalek, M., Prueksaritanont, T., & Kelley, R. F. (2017) · mAbs · doi:10.1080/19420862.2017.1323160 · Cited by 45
A potent erythropoietin-mimicking human antibody interacts through a novel binding site
Liu, Z., Stoll, V. S., DeVries, P. J., Jakob, C. G., Xie, N., Simmer, R. L., Lacy, S. E., Egan, D. A., Harlan, J. E., Lesniewski, R. R., et al. (2007) · Blood · doi:10.1182/blood-2007-04-083998 · Cited by 43
Kellner, C., Zhukovsky, E. A., Pötzke, A., Brüggemann, M., Schrauder, A., Schrappe, M., Kneba, M., Repp, R., Humpe, A., Gramatzki, M., et al. (2013) · Leukemia · doi:10.1038/leu.2012.373 · Cited by 43
Fcγ receptors enable anticancer action of proapoptotic and immune-modulatory antibodies
Kim, J. M., & Ashkenazi, A. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20131625 · Cited by 43
Monoclonal antibody biosimilars
Udpa, N., & Million, R. P. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.12 · Cited by 43
Erratum: Opportunities for therapeutic antibodies directed at G-protein-coupled receptors
Hutchings, C. J., Koglin, M., Olson, W. C., & Marshall, F. H. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.173 · Cited by 43
Jacobs, I. A., Petersel, D. L., Shane, L. G., Ng, C.-K., Kirchhoff, C. F., Finch, G. L., & Lula, S. (2016) · BioDrugs · doi:10.1007/s40259-016-0199-9 · Cited by 42
Discovery of Functional Antibodies Targeting Ion Channels
Wilkinson, T. C. I., Gardener, M. J., & Williams, W. A. (2014) · SLAS DISCOVERY · doi:10.1177/1087057114560698 · Cited by 41
Le, K., Gibiansky, L. V., Campagne, M. V. L., Good, J., Davancaze, T., Loyet, K., Morimoto, A. M., Strauss, E., & Jin, J. (2015) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12031 · Cited by 40
Hervé, V., Rabbe, N., Guilleminault, L., Paul, F., Schlick, L., Azzopardi, N., Duruisseaux, M., Fouquenet, D., Montharu, J., Rédiní, F., et al. (2014) · mAbs · doi:10.4161/mabs.34454 · Cited by 36
An Agonist Murine Monoclonal Antibody to the Human c-Mpl Receptor Stimulates Megakaryocytopoiesis
Deng, B., Banu, N., Malloy, B., Hass, P. E., Wang, J. F., Cavacini, L. A., Eaton, D., & Avraham, H. K. (1998) · Blood · doi:10.1182/blood.v92.6.1981 · Cited by 35
Cost-Effectiveness and Clinical Practice Guidelines: Have We Reached a Tipping Point?—An Overview
Garrison, L. P. (2016) · Value in Health · doi:10.1016/j.jval.2016.04.018 · Cited by 34
Chaperone proteins as single component reagents to assess antibody nonspecificity
Kelly, R. L., Geoghegan, J. C., Feldman, J. E., Jain, T. S., Kauke, M. J., Le, D., Zhao, J., & Wittrup, K. D. (2017) · mAbs · doi:10.1080/19420862.2017.1356529 · Cited by 33
TRAIL-R2 Superoligomerization Induced by Human Monoclonal Agonistic Antibody KMTR2
Tamada, T., Shinmi, D., Ikeda, M., Yonezawa, Y., Kataoka, S., Kuroki, R., Mori, E., & Motoki, K. (2015) · Scientific Reports · doi:10.1038/srep17936 · Cited by 31
Screening-based approaches to identify small molecules that inhibit protein–protein interactions
Choi, S., & Choi, K.-Y. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1280456 · Cited by 29
Ng, C. M., Loyet, K. M., Iyer, S., Fielder, P. J., & Deng, R. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.08.033 · Cited by 29
Tammen, A., Derer, S., Schwanbeck, R., Rösner, T., Kretschmer, A., Beurskens, F. J. M., Schuurman, J., Parren, P. W. H. I., & Valerius, T. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601268 · Cited by 29
Single-Batch Production of Recombinant Human Polyclonal Antibodies
Nielsen, L. S., Baer, A. S., Müller, C. R., Gregersen, K., Mønster, N. T., Rasmussen, S. K., Weilguny, D., & Tolstrup, A. B. (2010) · Molecular Biotechnology · doi:10.1007/s12033-010-9270-9 · Cited by 28
Casaz, P., Boucher, E. N., Wollacott, R., Pierce, B. G., Rivera, R., Sedic, M., Ozturk, S. S., Thomas, W. D., & Wang, Y. (2014) · mAbs · doi:10.4161/19420862.2014.975658 · Cited by 26
Inhaled Insulin: A Clinical and Historical Review
Chan, J., & Cheng-Lai, A. (2017) · Cardiology in Review · doi:10.1097/crd.0000000000000143 · Cited by 26
Evolutionary Survey of Druggable Protein Targets with Respect to Their Subcellular Localizations
Wang, X., Wang, R., Zhang, Y., & Zhang, H. (2013) · Genome Biology and Evolution · doi:10.1093/gbe/evt092 · Cited by 21
Sampei, Z., Igawa, T., Soeda, T., Funaki, M., Yoshihashi, K., Kitazawa, T., Muto, A., Kojima, T., Nakamura, S., & Hattori, K. (2014) · mAbs · doi:10.4161/19420862.2015.989028 · Cited by 20
Schuurman, J., & Parren, P. W. H. I. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.04.001 · Cited by 20
Antibody mimicry, receptors and clinical applications
Horenstein, A. L., Chillemi, A., Quarona, V., Zito, A., Mariani, V., Faini, A. C., Morandi, F., Schiavoni, I., Ausiello, C. M., & Malavasi, F. (2016) · Human Antibodies · doi:10.3233/hab-160305 · Cited by 16
Corti, D., & Kearns, J. D. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.03.001 · Cited by 13
Industry 'road tests' new wave of immune checkpoints
Garber, K. (2017) · Nature Biotechnology · doi:10.1038/nbt0617-487 · Cited by 13
Muzammil, S., Mabus, J. R., Cooper, P. R., Brezski, R. J., Bement, C. B., Perkinson, R. A., Huebert, N. D., Thompson, S. E., Levine, D., Kliwinski, C. M., et al. (2016) · Pharmacology Research & Perspectives · doi:10.1002/prp2.218 · Cited by 12
Oligoclonal antibodies to target the ErbB family
D’Souza, J. W., & Robinson, M. K. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1042362 · Cited by 8
Wilmes, G. M., Carey, K. L., Hicks, S. W., Russell, H. H., Stevenson, J. A., Kocjan, P., Lutz, S. R., Quesenberry, R. S., Shulga-Morskoy, S. V., Lewis, M. E., et al. (2014) · mAbs · doi:10.4161/mabs.28917 · Cited by 3
Cited by
Shimabukuro-Vornhagen, A., Gödel, P., Subklewe, M., Stemmler, H. J., Schlößer, H. A., Schlaak, M., Kochanek, M., Böll, B., & von Bergwelt-Baildon, M. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0343-9 · Cited by 1,656
Inflammation and atherosclerosis: signaling pathways and therapeutic intervention
Kong, P., Cui, Z.-Y., Huang, X.-F., Zhang, D.-D., Guo, R.-J., & Han, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00955-7 · Cited by 1,183
Unlocking the potential of antibody–drug conjugates for cancer therapy
Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,150
Lu, H., Zhou, Q., He, J., Jiang, Z., Peng, C., Tong, R., & Shi, J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00315-3 · Cited by 891
Antibody–drug conjugates for cancer
Chau, C. H., Steeg, P. S., & Figg, W. D. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31774-x · Cited by 816
Metadata
- Authors
- Carter, P. J., & Lazar, G. A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2017-12-01
- Volume
- 17
- Issue
- 3
- Pages
- 197-223
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2774294088
- Cited by
- 754
- References
- 293
- FWCI
- 10.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.